Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05258838 Recruiting - Psoriasis Clinical Trials

Tunisian National Registry on Psoriasis

PsoTReg
Start date: July 12, 2022
Phase:
Study type: Observational

National cross-sectional multicentric study to describe the epidemiological characteristics of patients with Psoriasis in Tunisia

NCT ID: NCT05258331 Recruiting - Clinical trials for Moderate to Severe Plaque Psoriasis

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis

NCT ID: NCT05254249 Recruiting - Psoriasis Vulgaris Clinical Trials

Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris

Start date: February 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection, obesity, smoking, and drugs. The provision of probiotic Lactobacillus plantarum IS-10506, an Indonesian original probiotic strain, is expected to be an effective, safe, and affordable alternative for psoriasis treatment for psoriasis patients in Indonesia. This study aimed to evaluate changes in gut microbiota profile, cytokines IL-17, TNF-a, IL-10, Foxp3, and disease severity of psoriasis vulgaris patients after supplementation with Lactobacillus plantarum IS-10506. The results of this study are expected to be the basis for the use of Lactobacillus plantarum IS-10506 in the therapy of psoriasis vulgaris which is included in the Clinical Practice Guide in Indonesia, which will ultimately help improve the quality of life of psoriasis patients.

NCT ID: NCT05252741 Recruiting - Psoriasis Clinical Trials

Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis.

Start date: February 20, 2022
Phase: N/A
Study type: Interventional

Psoriasis is an immune-mediated chronic inflammatory skin disease associated with increase interaction of inflammatory mediators like adipokines. Pigment epithelium-derived factor (PEDF) is one of the most abundant adipokines and have anti-angiogenesis effect. There is a study showed that PEDF level is up-regulated in the sera of psoriasis patients.

NCT ID: NCT05249972 Recruiting - Clinical trials for Mild to Moderate Psoriasis

A Phase III Study in Subjects With Mild to Moderate Psoriasis.

AKVANO-AKP02
Start date: January 24, 2022
Phase: Phase 3
Study type: Interventional

A randomized, assessor blind, parallel group, three arms, active and placebo controlled study with objective to demonstrate therapeutic non-inferiority of AKP02 cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO) versus Enstilar cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g) in subjects with mild to moderate plaque psoriasis.

NCT ID: NCT05243303 Recruiting - Psoriasis Vulgaris Clinical Trials

Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation

Start date: April 26, 2022
Phase: N/A
Study type: Interventional

The human body responds to inflammation, such as psoriatic skin lesions, by activating the cholinergic anti-inflammatory pathway. In patients with plaque psoriasis, this pathway is not sufficient to clear the skin lesions. Importantly, the vagus nerve, that is part of the anti-inflammatory pathway, also innervates the ear where it can be activated through non-invasive transcutaneous auricular vagus nerve stimulation (taVNS). This raises the research question if taVNS - added to standard of care - improves the symptoms of plaque psoriasis by augmenting the function of the cholinergic anti-inflammatory pathway. Thus, the aim of this project is to test the hypothesis that daily taVNS applied for 3 months results in anti-inflammatory actions and improvements in the Psoriasis Area and Severity Index (PASI). Potential anti-inflammatory actions of taVNS compared to a sham-taVNS control group will be assessed by plasma cytokine levels, flow cytometry, and cell culture experiments. This project is potentially significant, because it may demonstrate that taVNS lessens the symptoms of plaque psoriasis and, therefore, improves the quality of life of millions of patients.

NCT ID: NCT05225493 Recruiting - HIV Infections Clinical Trials

HIV Indicator Diseases in Hospital and Primary Care

#AwareHIV
Start date: January 1, 2020
Phase:
Study type: Observational

Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner. Testing for HIV is indicated with HIV indicator disorder but often omitted in clinical work-up. Besides the fact that HIV testing is forgotten, there are other reasons such as an underestimation of the risk of HIV in the event of indicator disorders, stigma and difficulties in discussing the test with a patient. Also and more relevant for primary care than for the hospital, practical challenges can exist for a patient to go to a laboratory, or costs are a hurdle. This project focuses on improving HIV indicator condition driven testing in different settings of the HIV epidemic, initially in the Netherlands as low HIV prevalence setting followed by an assessment of its benefit in different international settings. A specific focus will also be on the Rotterdam area in the Netherlands which has a high prevalence of undiagnosed HIV in the Netherlands. The ultimate aim is to decrease the number of undiagnosed HIV in populations, improve the 90-90-90 HIV cascade of care goals particularly its first pillar, and to help supporting the UNAIDS goal to end HIV/AIDS

NCT ID: NCT05203315 Recruiting - Plaque Psoriasis Clinical Trials

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

Start date: January 13, 2022
Phase: Phase 3
Study type: Interventional

This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.

NCT ID: NCT05200598 Recruiting - Clinical trials for Cardiovascular Diseases

Cardiovascular Risk Predictors in Patients With Psoriasis

Start date: October 1, 2021
Phase:
Study type: Observational

The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

NCT ID: NCT05184699 Recruiting - Psoriasis Clinical Trials

The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The food supplement Endocalyx is considered to support the endothelial glycocalyx integrity by supplying sulfated polysaccharides, anti-oxidant enzymes and additional substrates for glycocalyx synthesis. The investigators will study the effect of Endocalyx on endothelial, vascular and left ventricular myocardial function in patients with psoriatic disease.